Mycobacterium Tuberculosis Cell Wall Assembly
结核分枝杆菌细胞壁组装
基本信息
- 批准号:9089894
- 负责人:
- 金额:$ 22.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-07-01 至 2018-06-30
- 项目状态:已结题
- 来源:
- 关键词:ActinsAddressAnabolismAnti-Bacterial AgentsAntibioticsBacillus (bacterium)Bacillus subtilisBacteriaBiochemicalBiological AssayCell WallCell divisionCellsChemistryCollaborationsColoradoComplexContractsCorynebacterium glutamicumDevelopmentEnzymesFamilyFutureGene ClusterGenesGeneticGenomeGenus MycobacteriumGram-Positive BacteriaGrowthHealthHomologous GeneIn VitroIncidenceIndividualInstitutesJapanKnock-outKnowledgeLigaseLinkMapsMediatingMolecularMulti-Drug ResistanceMuramidaseMusMycobacterium tuberculosisMycobacterium tuberculosis H37RvN-acetylglucopyranosylamineNational Institute of Allergy and Infectious DiseaseParentsPathway interactionsPeptidoglycanPhenotypePhysiologicalPhysiological ProcessesPhysiologyPlayPredispositionProteinsRecombinantsResistanceRoleShapesSiteStaphylococcus aureusStructureTeichoic AcidsTestingTherapeuticTherapeutic StudiesTokyoTransferaseUniversitiesValidationVirulencearabinogalactanbasecell assemblycell envelopedesignin vitro Assayin vivoinhibitor/antagonistinnovationinorganic phosphateinsightknock-downlipoteichoic acidmacromoleculemicrobialmutantmycobacterialnovelnovel strategiespathogenpermissivenessprogramsresearch studyresistant strainretinal rodsscaffoldscreeningtranslocasetuberculosis drugs
项目摘要
DESCRIPTION (provided by applicant): The cell envelope of Mycobacterium tuberculosis (Mtb) is the basis of many of the physiological and pathogenic features of this bacterial pathogen and the site of susceptibility and resistance to many anti- tuberculosis drugs. In spite of being Gram-positive bacteria, mycobacteria are unique in having a cell wall devoid of (lipo)teichoic acids and instead containing a heteropolysaccharide known as the arabinogalactan (AG) covalently attached to peptidoglycan (PG). To this date, the cell wall ligase(s) responsible for the covalent attachment of these two macromolecules has/have defied definition. Despite the fundamental structural differences that exist between AG and wall teichoic acids (WTA), the structure of the unit linking AG to PG in mycobacteria shares similarities with the linker involved in the covalent attachment of WTA to PG in many Gram-positive bacteria. Enzymes of the widespread LytR-Cps2A-Psr (LCP) family were recently identified as the likely ligases mediating WTA-PG attachment in Bacillus subtilis and Staphylococcus aureus. We identified three LCP-like proteins in the genome of Mtb H37Rv, one of them mapping to an AG biosynthetic gene cluster. We here propose to use a combination of genetic and biochemical approaches to determine whether these three LCP homologs are the long sought mycobacterial cell wall ligases and to define their therapeutic potential. In particula, we will test whether two novel antibacterial compounds, caprazamycin B and CPZEN-45, products of a collaboration with the Institute of Microbial Chemistry (BIKAKEN, Tokyo, Japan) that inhibit mechanistically similar enzymes in mycobacterial cell wall assembly (MraY and WecA, respectively) may represent promising scaffolds for the future development of inhibitors targeting the assembly of the mycobacterial cell wall. Similar to the situation with WTA ligases, i is likely that the ligase(s) of Mtb interact(s) with other wall proteins to coordinate cell wall synthesis with cell elongation and cell division. The characterization of Mtb's ligase(s) therefore
also represents an important first step toward the elucidation of this key aspect of the physiology
of mycobacteria and the future design of innovative therapeutic strategies aimed at targeting cell elongation and division.
描述(由申请人提供):结核分枝杆菌(Mtb)的细胞包膜是该细菌病原体的许多生理和致病特征的基础,也是对许多抗结核药物敏感和耐药的部位。尽管是革兰氏阳性细菌,但分枝杆菌的独特之处在于其细胞壁不含(脂)磷壁酸,而是含有共价连接至肽聚糖(PG)的称为阿拉伯半乳聚糖(AG)的杂多糖。迄今为止,负责这两种大分子共价连接的细胞壁连接酶尚未定义。尽管AG和壁磷壁酸(WTA)之间存在基本的结构差异,但分枝杆菌中连接AG与PG的单元的结构与许多革兰氏阳性细菌中参与WTA与PG共价连接的接头具有相似性。广泛分布的LytR-Cps 2A-Psr(LCP)家族的酶最近被鉴定为枯草芽孢杆菌和金黄色葡萄球菌中可能的介导WTA-PG附着的连接酶。我们在结核分枝杆菌H37 Rv基因组中鉴定了三种LCP样蛋白,其中一种定位于AG生物合成基因簇。在这里,我们建议使用遗传和生化方法的组合,以确定这三个LCP同系物是否是长期寻求分枝杆菌细胞壁连接酶,并确定其治疗潜力。特别是,我们将测试两种新的抗菌化合物,caprazamycin B和CPZEN-45,与微生物化学研究所(BIKAKEN,东京,日本)的合作产品,抑制分枝杆菌细胞壁组装(MraY和WecA,分别)的机制相似的酶,可能代表未来发展的抑制剂靶向分枝杆菌细胞壁的组装有前途的支架。与WTA连接酶的情况类似,Mtb的连接酶可能与其他壁蛋白相互作用以协调细胞壁合成与细胞伸长和细胞分裂。因此,Mtb连接酶的表征
也代表了阐明生理学的这一关键方面的重要的第一步
的分枝杆菌和未来的设计创新的治疗策略,旨在针对细胞的延伸和分裂。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mary Jackson其他文献
Mary Jackson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mary Jackson', 18)}}的其他基金
Repurposing antimalarials for the treatment of NTM infections
重新利用抗疟药治疗 NTM 感染
- 批准号:
10646331 - 财政年份:2022
- 资助金额:
$ 22.65万 - 项目类别:
Repurposing antimalarials for the treatment of NTM infections
重新利用抗疟药治疗 NTM 感染
- 批准号:
10494711 - 财政年份:2022
- 资助金额:
$ 22.65万 - 项目类别:
Assembly and export of mycobacterial lipoglycans
分枝杆菌脂聚糖的组装和输出
- 批准号:
10620764 - 财政年份:2021
- 资助金额:
$ 22.65万 - 项目类别:
Assembly and export of mycobacterial lipoglycans
分枝杆菌脂聚糖的组装和输出
- 批准号:
10291355 - 财政年份:2021
- 资助金额:
$ 22.65万 - 项目类别:
Assembly and export of mycobacterial lipoglycans
分枝杆菌脂聚糖的组装和输出
- 批准号:
10426356 - 财政年份:2021
- 资助金额:
$ 22.65万 - 项目类别:
Adjunct therapeutic potential of a repurposed drug inhibiting Mycobacterium abscessus biofilm formation
抑制脓肿分枝杆菌生物膜形成的再利用药物的辅助治疗潜力
- 批准号:
10172839 - 财政年份:2020
- 资助金额:
$ 22.65万 - 项目类别:
Inhibitors of Mycobacterium tuberculosis FAS-II dehydratases
结核分枝杆菌 FAS-II 脱水酶抑制剂
- 批准号:
10190829 - 财政年份:2020
- 资助金额:
$ 22.65万 - 项目类别:
Recombinant BCG-based SARS-CoV-2 vaccine
基于 BCG 的重组 SARS-CoV-2 疫苗
- 批准号:
10171055 - 财政年份:2020
- 资助金额:
$ 22.65万 - 项目类别:
Inhibitors of Mycobacterium tuberculosis FAS-II dehydratases
结核分枝杆菌 FAS-II 脱水酶抑制剂
- 批准号:
10038295 - 财政年份:2020
- 资助金额:
$ 22.65万 - 项目类别:
2019 Tuberculosis Drug Discovery and Development GRC: Shortening the Duration of Tuberculosis Chemotherapy and GRS
2019结核病药物发现与开发GRC:缩短结核病化疗和GRS的持续时间
- 批准号:
9750348 - 财政年份:2019
- 资助金额:
$ 22.65万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 22.65万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 22.65万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 22.65万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 22.65万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 22.65万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 22.65万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 22.65万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 22.65万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 22.65万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 22.65万 - 项目类别:
Research Grant